About AnaptysBio, Inc.
https://www.anaptysbio.comAnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications.
CEO
Daniel R. Faga
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 119
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Stifel
Buy
HC Wainwright & Co.
Buy
Guggenheim
Buy
Wedbush
Outperform
Barclays
Overweight
Wells Fargo
Overweight
Grade Summary
Showing Top 6 of 9
Price Target
Institutional Ownership
ECOR1 CAPITAL, LLC
Shares:7.88M
Value:$396.05M
POINT72 ASSET MANAGEMENT, L.P.
Shares:2.27M
Value:$113.87M
BLACKROCK INC.
Shares:1.77M
Value:$88.96M
Summary
Showing Top 3 of 193
About AnaptysBio, Inc.
https://www.anaptysbio.comAnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $76.32M ▲ | $10.21M ▼ | $15.11M ▲ | 19.8% ▲ | $0.54 ▲ | $38.24M ▲ |
| Q2-2025 | $22.26M ▼ | $10.61M ▼ | $-38.63M ▲ | -173.52% ▼ | $-1.34 ▼ | $-18.38M ▲ |
| Q1-2025 | $27.77M ▼ | $14.13M ▲ | $-39.33M ▼ | -141.62% ▼ | $-1.28 ▼ | $-20.62M ▼ |
| Q4-2024 | $43.11M ▲ | $10.19M ▼ | $-21.78M ▲ | -50.53% ▲ | $-0.77 ▲ | $-3.81M ▲ |
| Q3-2024 | $30.02M | $10.56M | $-32.85M | -109.44% | $-1.14 | $-16.84M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $248.96M ▼ | $353.1M ▲ | $382.51M ▲ | $-29.42M ▲ |
| Q2-2025 | $265.71M ▼ | $335.25M ▼ | $379.98M ▼ | $-44.73M ▼ |
| Q1-2025 | $339.94M ▼ | $422.05M ▼ | $388.03M ▼ | $34.02M ▼ |
| Q4-2024 | $385.37M ▼ | $483.83M ▼ | $412.97M ▲ | $70.87M ▼ |
| Q3-2024 | $430.12M | $493.42M | $409.05M | $84.37M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $15.11M ▲ | $-27.36M ▲ | $103.28M ▲ | $-10.39M ▲ | $65.53M ▲ | $-27.37M ▲ |
| Q2-2025 | $-38.63M ▲ | $-40.24M ▼ | $36.4M ▲ | $-50.5M ▼ | $-54.34M ▼ | $-40.28M ▼ |
| Q1-2025 | $-39.33M ▼ | $-10.7M ▲ | $14.85M ▲ | $-28.59M ▼ | $-24.44M ▲ | $-10.73M ▲ |
| Q4-2024 | $-21.78M ▲ | $-66.67M ▼ | $-29.4M ▼ | $27.57M ▼ | $-68.5M ▼ | $-66.94M ▼ |
| Q3-2024 | $-32.85M | $-10.09M | $58.62M | $71.23M | $119.76M | $-10.13M |
CEO
Daniel R. Faga
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 119
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Stifel
Buy
HC Wainwright & Co.
Buy
Guggenheim
Buy
Wedbush
Outperform
Barclays
Overweight
Wells Fargo
Overweight
Grade Summary
Showing Top 6 of 9
Price Target
Institutional Ownership
ECOR1 CAPITAL, LLC
Shares:7.88M
Value:$396.05M
POINT72 ASSET MANAGEMENT, L.P.
Shares:2.27M
Value:$113.87M
BLACKROCK INC.
Shares:1.77M
Value:$88.96M
Summary
Showing Top 3 of 193